Current state of Anti-Anaerobic Therapy | CMAC

Current state of Anti-Anaerobic Therapy

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(4):298-313

Type
Journal article

Abstract

Over the last years there is an increase in number of publications that address to the failure of empirical therapy of anaerobic infections which is due to the antimicrobial resistance of pathogens. Hence, it is important to have valid local data on resistance to the currently used antimicrobials in clinically significant anaerobes. This paper describes the main characteristics of anaerobic infections, and trends of resistance to the commonly used antibiotics in anaerobes. Strategy of the empiric choice of antibiotic for the treatment of anaerobic infections was proposed based on the results of susceptibility testing of the most common anaerobes isolated from patients in Smolensk hospitals. This local study indicates that carbapenems (imipenem, meropenem, ertapenem), nitroimidazoles (metronidazole, ornidazole), inhibitorprotected b-lactams (amoxicillin/clavulanate, amoxicillin/ sulbactam, cefoperazone/sulbactam) and IV generation fluoroquinolones (moxifloxacin) are currently the drugs of choice for the empirical antimicrobial therapy of anaerobic infections.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared